ReviewFrontiers in cardiovascular medicine2021
Latest Advances in Endothelial Progenitor Cell-Derived Extracellular Vesicles Translation to the Clinic.
Review in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 29 citations in OpenAlex.
- The Role and Mechanism of Endothelial Progenitor Cell-Derived Extracellular Vesicles in Vascular Repair of Ischemic Heart Disease.Journal of cardiovascular translational research · 2026Review
- Review
- Cell and extracellular vesicle therapies for AKI in critical care: clinical translation, organ-support integration, and lessons learned.Frontiers in medicine · 2026Review
- Cell Membrane- and Vesicle-Based Bionic Nanodrugs: Applications in Central Nervous System Diseases and Exploration of Nasal-Cerebral Delivery.Gels (Basel, Switzerland) · 2025Review
- Unleashing the potential of extracellular vesicles for ulcerative colitis and Crohn's disease therapy.Bioactive materials · 2025Review
- The Angiogenic Repertoire of Stem Cell Extracellular Vesicles: Demystifying the Molecular Underpinnings for Wound Healing Applications.Stem cell reviews and reports · 2024Review
- Anti-inflammatory Prowess of endothelial progenitor cells in the realm of biology and medicine.NPJ Regenerative medicine · 2024Review
- Endothelial progenitor cells for diabetic cardiac and kidney disease.Stem cells translational medicine · 2024Review
- Endothelial progenitor cell-derived extracellular vesicles: the world of potential prospects for the treatment of cardiovascular diseases.Cell & bioscience · 2024Review
- Treatment of medication-related osteonecrosis of the jaw with cell therapy.Frontiers in cell and developmental biology · 2024Article
- Human Umbilical Cord Blood Endothelial Progenitor Cell-Derived Extracellular Vesicles Control Important Endothelial Cell Functions.International journal of molecular sciences · 2023Article
- Repetitive administration of cultured human CD34+ cells improve adenine-induced kidney injury in mice.World journal of stem cells · 2023Article
- Potential of Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Natural Nanocarriers: Concise Review.Pharmaceutics · 2023Review
- Endothelial Progenitor Cells Affect the Growth and Apoptosis of Renal Cells by Secreting Microvesicles Carrying Dysregulated miR-205 and miR-206.Disease markers · 2023Article
- Endothelial progenitor cells in the host defense response.Pharmacology & therapeutics · 2023Review
- Endothelial progenitor cell-derived small extracellular vesicles for myocardial angiogenesis and revascularization.Journal of clinical and translational research · 2022Review
- Review
- Characterization of Endothelial Progenitor Cell: Past, Present, and Future.International journal of molecular sciences · 2022Review
- Comprehensive insight into endothelial progenitor cell-derived extracellular vesicles as a promising candidate for disease treatment.Stem cell research & therapy · 2022Review
- Endothelial Progenitor Cells as Biomarkers of Cardiovascular Pathologies: A Narrative Review.Cells · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Almost all nucleated cells secrete extracellular vesicles (EVs) that are heterogeneous spheroid patterned or round shape particles ranging from 30 to 200 nm in size. Recent preclinical and clinical studies have shown that endothelial progenitor cell-derived EVs (EPC-EVs) have a beneficial therapeutic effect in various diseases, including cardiovascular diseases and kidney, and lung disorders. Moreover, some animal studies have shown that EPC-EVs selectively accumulate at the injury site with a specific mechanism of binding along with angiogenic and restorative effects that are superior to those of their ancestors. This review article highlights current advances in the biogenesis, delivery route, and long-term storage methods of EPC-EVs and their favorable effects such as anti-inflammatory, angiogenic, and tissue protection in various diseases. Finally, we review the possibility of therapeutic application of EPC-EVs in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.